Common Terminology Criteria for Adverse Events

The Common Terminology Criteria for Adverse Events (CTCAE),^[1] formerly called the Common Toxicity Criteria (CTC or NCI-CTC), are a set of criteria for the standardized classification of adverse events of drugs and treatment used in cancer therapy. The CTCAE system is a product of the US National Cancer Institute (NCI).

The first Iteration was prior to 1998. In 1999, the FDA released version 2.0. CTCAE version 4.0 in 2009 with an update to y version 4.03 in 2010.^[2] The current version 5.0 was released on November 27, 2017. Many clinical trials, now extending beyond oncology, encode their observations based on the CTCAE system. It uses a range of grades from 1 to 5. Specific conditions and symptoms may have values or descriptive comment for each level, but the general guideline is:

1 - Mild

2 - Moderate

3 - Severe

4 - Life-threatening

5 - Death

Grade 1: is defined as mild, asymptomatic symptoms. Clinical or diagnostic observations only; Intervention not indicated. Grade 2: is moderate; minimal, local or noninvasive intervention was needed. Grade 3: Severe symptoms or medically significant but not life-threatening but may be disabling or limit self care in ADL Grade 4: is Life threatening consequences; urgent or emergent intervention needed Grade 5: Death related to or due to adverse event^[3]

See also

• Adverse event – Any event, symptom, or disease occurring during a medical treatment
• Cancer research – Research into causes and treatment of cancer
• EudraVigilance – Processing NetworkPages displaying wikidata descriptions as a fallback
• Good clinical practice – International quality standard for drug testing and production
• National Cancer Institute – American governmental health agency
• Pharmacovigilance – Drug safety; subdiscipline of pharmacy relating to prevention of adverse effects of drugs